OBJECTIVE: To evaluate long-term outcomes of 60 extremely low birth weight (ELBW) infants treated with or without three injections of high-dose erythropoietin (Epo). STUDY DESIGN: A retrospective analysis of anthropometric and neurodevelopmental outcome data comparing 30 ELBW infants enrolled in a phase I/II study examining the pharmacokinetics of high-dose Epo (500, 1000 and 2500 U/kg × 3 doses) administered to 30 concurrent controls. RESULT: Birth characteristics and growth from 4 to 36 months were similar for untreated and Epo-treated patients. Multiple linear regression analysis of neurodevelopmental follow-up scores from 17/25 Epo-treated and 18/26 control infants identified that Epo correlated with improvement of cognitive (R=0.22, P=0.044) and motor (R=0.15, P=0.026) scores. No negative long-term effects of Epo treatment were evident. CONCLUSION: Retrospective analysis of the only available long-term follow-up data from ELBW infants given high-dose Epo treatment suggests that Epo treatment is safe and correlates with modest improvement of neurodevelopmental outcomes.
OBJECTIVE: To evaluate long-term outcomes of 60 extremely low birth weight (ELBW) infants treated with or without three injections of high-dose erythropoietin (Epo). STUDY DESIGN: A retrospective analysis of anthropometric and neurodevelopmental outcome data comparing 30 ELBW infants enrolled in a phase I/II study examining the pharmacokinetics of high-dose Epo (500, 1000 and 2500 U/kg × 3 doses) administered to 30 concurrent controls. RESULT: Birth characteristics and growth from 4 to 36 months were similar for untreated and Epo-treated patients. Multiple linear regression analysis of neurodevelopmental follow-up scores from 17/25 Epo-treated and 18/26 control infants identified that Epo correlated with improvement of cognitive (R=0.22, P=0.044) and motor (R=0.15, P=0.026) scores. No negative long-term effects of Epo treatment were evident. CONCLUSION: Retrospective analysis of the only available long-term follow-up data from ELBW infants given high-dose Epo treatment suggests that Epo treatment is safe and correlates with modest improvement of neurodevelopmental outcomes.
Authors: Robin K Ohls; Richard A Ehrenkranz; Abhik Das; Anna M Dusick; Kimberly Yolton; Elaine Romano; Virginia Delaney-Black; Lu-Ann Papile; Neal P Simon; Jean J Steichen; Kimberly G Lee Journal: Pediatrics Date: 2004-11 Impact factor: 7.124
Authors: Sandra E Juul; Ronald J McPherson; Larry A Bauer; Kelly J Ledbetter; Christine A Gleason; Dennis E Mayock Journal: Pediatrics Date: 2008-08 Impact factor: 7.124
Authors: Robin K Ohls; Daniel C Cannon; John Phillips; Arvind Caprihan; Shrena Patel; Sarah Winter; Michael Steffen; Ronald A Yeo; Richard Campbell; Susan Wiedmeier; Shawna Baker; Sean Gonzales; Jean Lowe Journal: Pediatrics Date: 2016-02-15 Impact factor: 7.124
Authors: Robin K Ohls; Beena D Kamath-Rayne; Robert D Christensen; Susan E Wiedmeier; Adam Rosenberg; Janell Fuller; Conra Backstrom Lacy; Mahshid Roohi; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Hannah Peceny; Daniel C Cannon; Jean R Lowe Journal: Pediatrics Date: 2014-05-12 Impact factor: 7.124
Authors: Robin K Ohls; Robert D Christensen; Beena D Kamath-Rayne; Adam Rosenberg; Susan E Wiedmeier; Mahshid Roohi; Conra Backstrom Lacy; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Ron Schrader; Jean R Lowe Journal: Pediatrics Date: 2013-06-17 Impact factor: 7.124
Authors: Samantha K Barton; Annie R A McDougall; Jacqueline M Melville; Timothy J M Moss; Valerie A Zahra; Tammy Lim; Kelly J Crossley; Graeme R Polglase; Mary Tolcos Journal: J Physiol Date: 2015-10-08 Impact factor: 5.182